Sinaptica Therapeutics

Positive 52-week Alzheimer's data presented today at #CTAD2024: Our personalized #neuromodulation therapy met primary and key secondary endpoints including CDR-SB, ADAS- Cog11 and NPI, showing strong separation from placebo and statistical significance in mild-to-moderate patients, with no serious side-effects. The treatment slowed Alzheimer’s in all 3 clinically measured domains: cognition, function, and behavior, and on one key functional measure, Activities of Daily Living (ADCS-ADL), Alzheimer’s disease patients receiving treatment were nearly unchanged after one year. #neurotech #innovation #MedTech #AlzMoonshot #ENDALZ https://lnkd.in/eGqZRJE2

We’re ready for 2025! Building on our positive 52-week data in #Alzheimers across all 3 clinically measured domains –  cognition, function, behavior – including Activites of Daily Living nearly unchaged after a year with  no serious side-effects, we’re preparing for our pivotal Phase 3 trial in mild-to-moderate Alzheimer’s disease. Watch for more news on our non-invasive   #neuromodulation this year! #MedTech #ENDALZ If you missed our positive clinical trial results, read more here:  https://lnkd.in/eGqZRJE2  

This holiday season, we reflect on all of the patients, families and caregivers living with #Alzheimers disease. Wishing all happy holidays full of memories, old and new. #ENDALZ #HappyHolidays

Healthcare Brew followed their earlier #neurotech feature with another article on recent progress in neurotechnology clincial trials, including Sinaptica, in coverage of #neuromodulation for #Alzheimers. 

#ICYMI – Don’t miss this article by NBC News on our positive 52-week data in mild-to-moderate #Alzheimers, meeting primary and key secondary endpoints, showing strong separation from placebo and statistical significance, with no serious side-effects.  #neuromodulation #HealthTech #neuroscience #neurotech    https://lnkd.in/eqb3R-uR  

#TBTuesday In #Newsweek’s "New Era of Life Sciences" feature section on #Alzheimers, we shared our “patented new Alzheimer's treatment based on precision non-invasive brain stimulation, a painless treatment with virtually no side effects.” See the full feature: https://lnkd.in/eyWABf52     #ENDALZ #neuromodulation #BrainHealth #HealthTech #connectomics, #personalizedmedicine #machinelearning #neuroscience #neurotech  

#ICYMI The Alzheimer's Drug Discovery Foundation (ADDF) and Gates Ventures are known for supporting out-of-the-box research, including the #AlzMoonshot – and we’re proud to be part of this innovative initiative. We appreciate that StartUp Health recognizes Sinaptica's precision #neuromodulation as a potential game-changer in #Alzheimers. Our unexpected neuromodulation-based breakthrough is changing how we think about the brain, Alzheimer’s, and treatment approaches. #ENDALZ #neuromodulation #BrainHealth #HealthTech #connectomics, #personalizedmedicine #machinelearning #neuroscience #neurotech    https://lnkd.in/e4t5TDpX

Our scientific co-founder Giacomo Koch MD, PhD, (lead author), along with our other scientific co-founder Emiliano Santarnecchi, PhD, PhD and Scientific Advisory Board member Giovanni Frisoni, MD (co-authors), put their decades of experience in #neuromodulation for #Alzheimers to good use as in a review article in the December issue of the journal Brain. This comprehensive overview provides an industry resource with all of the most promising approaches to non-invasive brain stimulation as a therapeutic for cognitive impairment and #Alzheimers.  Read the paper here: https://lnkd.in/eP6nQyNb  

Healthcare Brew features Sinaptica in this in-depth look at the renaissance in #neurotech therapies for #Alzheimers and other diseases.   #neuromodulation #BrainHealth #HealthTech #connectomics, #personalizedmedicine #machinelearning #neuroscience  Read the full article here:    https://lnkd.in/ehWwh8PZ  

Congratulations to our scientific co-founder Emiliano Santarnecchi PhD, PhD, who was honored as a #DistinguishedInvestigator at the Academy for Biological & Medical Imaging Research meeting #RSNA24 in Chicago last week. #innovator #neuromodulation #neurotech https://lnkd.in/e4c2Chqt